Find a Clinical Trial | Rutgers Cancer Institute of New Jersey

UPCC 02614: The BAMM Trial: BRAF, Autophagy and MEK inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients with Advanced BRAF Mutant Melanoma.

Protocol: 091503

Principal Investigator: Janice Mehnert

Applicable Disease Sites: Melanoma, skin

A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination with PD-1 Blocking Antibodies

Protocol: 051707

Principal Investigator: Ann Silk

Applicable Disease Sites: Eye and Orbit
Hodgkin's Lymphoma
Lip, Oral Cavity and Pharynx
Non-Hodgkin's Lymphoma
Brain and Nervous System
Colon
Ill-Defined Sites
Kidney
Liver
Other Urinary
Bladder
Lung
Melanoma, skin

The Development and Evaluation of a Behavioral Intervention to Reduce Indoor Tanning

Protocol: 131315

Principal Investigator: Jerod Stapleton

Applicable Disease Sites: Melanoma, skin

Sun Protection and Skin Self-Examination Among Families Coping With Early Onset Melanoma: A Pilot Study

Protocol: 131516

Principal Investigator: Sharon Manne

Applicable Disease Sites: Melanoma, skin

Couple-Focused ACT Intervention for Couples Coping with Cancer: A Pilot Study

Protocol: 131604

Principal Investigator: Sharon Manne

Applicable Disease Sites: Other Female Genital
Liver
Rectum
Colon
Melanoma, skin
Ovary
Breast - Female
Cervix Uteri
Lung
Other Skin

COG AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents.

Protocol: 111505

Principal Investigator: Richard Drachtman

Applicable Disease Sites: Hodgkin's Lymphoma